US stock anomaly | Novo Nordisk (NVO.US) up nearly 6% as oral weight loss drug from competitor Eli Lilly (LLY.US) is found to be less effective than expected.

According to the Securities Times app, on Thursday, Novo Nordisk's (NVO.US) stock price rose, rising nearly 6% to $47.99 at the time of publication. On the news front, the company's competitor Eli Lilly's (LLY.US) first small molecule oral GLP-1 drug Orforglipron achieved an average weight loss of 11.2%, lower than the expected 13% to 15% or more.